Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 31-37

  Vergnenègre, Alain ^a   Ray, Joshua A ^b   Chouaid, Christos ^c   Grossi, Francesco ^d   Bischoff, Helge G ^e   Heigener, David F ^f   Walzer, Stefan ^b  

^a Hopital du Cluzeau   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HÔPITAL SAINT ANTOINE   (France)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Cost effectiveness; Erlotinib; First line maintenance; Lung cancer; Non small cell lung cancer

Indexed keywords

ERLOTINIB; PLACEBO; PLATINUM COMPLEX;

AREA UNDER THE CURVE; ARTICLE; CANCER MORTALITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FRANCE; GERMANY; HEALTH STATUS; HUMAN; ITALY; LIFE EXPECTANCY; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84856766815     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S25923     Document Type: Article

References (29)

1. Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694-705.
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22(2):330-353.
3. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer v.2. Available from: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed May 18, 2011.
4. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii39-ii40.
5. National Institute for Health and Clinical Excellence. Clinical Guideline 24. Lung cancer. The diagnosis and treatment of lung cancer. Available from: http://www.nice.org.uk/nicemedia/pdf/CG024niceguideline.pdf. Accessed May 18, 2011.
6. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006;52(2):155-163.
7. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-598.
8. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11(6):521-529.
9. European Medicines Agency. Avastin summary of product characteristics. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf. Accessed December 15, 2010.
10. European Medicines Agency. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Tarceva. Available from: http://www.emea.europa.eu/pdfs/human/opinion/51116606en.pdf. Accessed May 18, 2011.
11. European Medicines Agency. Committee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Alimta. Available from: http://www.emea.europa.eu/pdfs/human/opinion/Alimta_9292908en.pdf. Accessed May 18, 2011.
12. European Medicines Agency Committee for medicinal products for human use (CHMP). Summary of opinion (post authorisation). Tarceva (erlotinib). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000618/WC500075850.pdf. Accessed May 18, 2011.
13. Weisstein EW. Gamma function. From 'MathWorld' - A Wolfram Web Resource. Available from: http://mathworld.wolfram.com/GammaFunction.html. Accessed May 18, 2011.
14. Collett D. Modelling Survival Data in Medical Research. 2nd ed. Boca Raton, FL: Chapman & Hall; 2003.
15. Official Gazette GHS 9606. Chemotherapy for tumors, in session. Available from: http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=244B4669551731582BF775EC93B44BD2.tpdjo09v_2?cidTexte=JORFTEXT000021879531&dateTexte=&oldAction=rechJO&categorieLien=id. Accessed January 20, 2011. French.
16. Gatzemeier U, Pirk O, Gabriel A, Kotowa W, Heigener D. Second-linetherapy for non-small cell lung cancer (NSCLC) - a retrospective cost analysis. Tumordiagn u Ther. 2008;29:211-217. German.
17. Conference of the Regions of Autonomous Provinces. Conventional single tariff for the provision of hospital care rules and rates applicable to the year 2009. Available from: http://www.regioni.it/upload/270110TUC_ASSISTENZA_OSPEDALIERA.pdf. Accessed May 18, 2011. Italian.
18. Briggs A, Schulpher M, Claxton K. Decision Modelling for Health Economic Evaluation. 1st ed. Oxford, UK: Oxford University Press; 2006.
19. Bischoff HG, Heigener D, Banz K, Walzer S. Costs of treating severe adverse events observed with a regimen of bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine in the first-line therapy of advanced non-small cell lung cancer (NSCLC) in Germany [abstract]. Value Health. 2009;12(7):A265; Abstr PCN47.
20. Chouaid C, Vergnenegre A, Brunner M, Walzer S. The cost of treating grade 3/4 adverse events related to first-line therapy with bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine for patients with advanced non-small cell lung cancer (NSCLC) in France [abstract]. Value Health. 2009;12(7):A264; Abstr PCN43.
21. Heigener D, Bischoff HG, Banz K, Walzer S. Cost savings related to superior adverse event profile of bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine in the first-line therapy of advanced non-small cell lung cancer (NSCLC) in Germany: a sensitivity analysis on the EGOG status [abstract]. Value Health. 2009;12(7);A265; Abstr PCN46.
22. Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010;5(8): 1263-1272.
23. Casciano R, Bischoff H, Nuijten M, Malangone E, Ray J. Maintenance erlotinib versus pemetrexed for the treatment of non-small cell lung cancer: indirect comparison applying real-life outcomes [abstract]. Value Health. 2010;13(7):A254, Abstr PCN20.
24. Ravera S, Walzer S, Ray J. Cost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer in Italy [abstract]. Value Health. 2010;13(7):A259; Abstr PCN43.
25. Castro de Carpeño J, Castro-Gómez AJ, Walzer S, Ray J. Cost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer in Spain [abstract]. Value Health. 2010;13(7):A259; Abstr PCN44.
26. Learn PA, Bach PB. Pem and the cost of multicycle maintenance. J Thorac Oncol. 2010;5(8):1111-1112.
27. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374(9699):1432-1440.
28. Nuijten MJ, de Castro Carpeño J, Chouaid C, et al. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer. 2011. In press.
29. Department of Health and Sports. Order of 27/02/2010 fixing for 2010 the tariff rules referred to in I and IV of Article L. 162-22-10 of the Code of Social Security and IV and V of the amended article 33 of the finance act 2004 for social security. Official Gazette No 50. 2010. French.